ArticleParasites & vectors2015
Highly discordant serology against Trypanosoma cruzi in central Veracruz, Mexico: role of the antigen used for diagnostic.
Article in Parasites & vectors, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Estimating the current burden of Chagas disease in Mexico: A systematic review and meta-analysis of epidemiological surveys from 2006 to 2017.PLoS neglected tropical diseases · 2019Pooled it
- Assessment of the Performance of Indirect Immunofluorescence Assay for Chagas Disease in Dogs Using a Reference Panel of Four Chimeric Proteins.Veterinary medicine and science · 2026Article
- Evaluation of a Novel Peptide-Based ELISA for the Serological Diagnosis of Trypanosoma cruzi Infection.Clinical and translational science · 2026Article
- Article
- A Trypanosoma cruzi trans-sialidase peptide demonstrates high serological prevalence among infected populations across endemic regions.The Journal of clinical investigation · 2026Article
- K-mer-based approach for serodiagnostic antigen discovery in Chagas disease using unassembled sequencing reads.PLoS neglected tropical diseases · 2025Article
- Serological surveillance of orally acquired acute Chagas disease in the Brazilian Amazon using conventional and in house assays.Scientific reports · 2025Article
- Rapid High-Sensitivity Detection of Antibodies to Trypanosoma cruzi With a Recombinant Tc24 Antigen-Based Magneto-Immunoassay: A Pilot Study.The Journal of infectious diseases · 2025Article
- Chronic Chagas Disease in the Brazilian Amazon: Serological Survey, Clinical Follow-Up, and Associated Risk Factors.The American journal of tropical medicine and hygiene · 2025Article
- Detection ofTropical medicine and infectious disease · 2025Article
- Serological determination of Trypanosoma cruzi in northern region of the State of Mexico.Parasitology research · 2025Article
- Identification of highly conservedEmerging microbes & infections · 2024Article
- Assessment of Alinity s ChagasLife (Basel, Switzerland) · 2024Article
- Diversity of Chagas disease diagnostic antigens: Successes and limitations.PLoS neglected tropical diseases · 2024Review
- Increased levels of anti-Encephalitozoon intestinalis antibodies in patients with colorectal cancer.PLoS neglected tropical diseases · 2024Article
- Retrospect, advances and challenges in Chagas disease diagnosis: a comprehensive review.Lancet regional health. Americas · 2024Review
- Increased Natural Killer (NK)-cell cytotoxicity and Trypanosoma cruzi-specific memory B cells in subjects with discordant serology for Chagas disease.Biochimica et biophysica acta. Molecular basis of disease · 2024Article
- The Trypanosoma cruzi Antigen and Epitope Atlas: antibody specificities in Chagas disease patients across the Americas.Nature communications · 2023Article
- Proof of Concept of a Novel Multiepitope Recombinant Protein for the Serodiagnosis of Patients with Chagas Disease.Pathogens (Basel, Switzerland) · 2023Article
- Clinical use of molecular methods forFrontiers in parasitology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChagas disease is a parasitic disease caused by the protozoan parasite Trypanosoma cruzi. In Mexico, the burden of the disease is difficult to estimate and improving surveillance for Chagas disease is an important priority. We aimed here at determining the seroprevalence of T. cruzi infection in humans in a rural community in Veracruz.
methodsSerum samples (196) were analyzed for T. cruzi infection using five enzyme-linked immunosorbent assay (ELISA) tests: two in-house tests based on crude parasite extract and three commercial ELISA kits. Because of highly discordant results, we further explored the importance of parasite antigens and strains by western-blot analysis.
resultsA total of 74 samples (37.7 %) were reactive with at least one ELISA, but discordance among tests was very high. The best agreement was between Chagatest recombinant and Chagatek ELISA (Kappa index = 0.798). The agreement between other combinations of tests ranged from 0.038 to 0.518. Discordant samples were confirmed by western-blot analysis using up to nine parasite strains, giving a seroprevalence of 33.7 %.
conclusionsCommercial tests had a very limited ability to detect T. cruzi infection in the study population. In-house tests based on crude parasite antigens showed a greater sensitivity but were still unable to detect all cases of T. cruzi infection, even when based on a local parasite strain. The high seroprevalence confirmed the hyper-endemicity of T. cruzi infection in the region. Reliable epidemiological surveillance of Chagas disease will require the development of improved diagnostic tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.